This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2016 Mar 10;34(8):769-71.

doi: 10.1200/JCO.2015.63.5938. Epub 2015 Sep 14.

Trabectedin and the L-Sarcomas: A Decade-Long Odyssey

Gary K Schwartz¹

Affiliations

PMID: 26371135
DOI: 10.1200/JCO.2015.63.5938

Editorial

Trabectedin and the L-Sarcomas: A Decade-Long Odyssey

Gary K Schwartz. J Clin Oncol. 2016.

. 2016 Mar 10;34(8):769-71.

doi: 10.1200/JCO.2015.63.5938. Epub 2015 Sep 14.

Author

Gary K Schwartz¹

Affiliation

¹ Columbia University School of Medicine, New York, NY schwartzg@columbia.edu.

PMID: 26371135
DOI: 10.1200/JCO.2015.63.5938

No abstract available

PubMed Disclaimer

Comment on

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Demetri GD, et al. J Clin Oncol. 2016 Mar 10;34(8):786-93. doi: 10.1200/JCO.2015.62.4734. Epub 2015 Sep 14. J Clin Oncol. 2016. PMID: 26371143 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information